Is ezetimbe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications

Cleveland Clinic Journal of Medicine

Volumn 75, Issue 7, 2008, Pages 479-491

  Davidson, Michael H ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZETIDINE DERIVATIVE; EZETIMIBE; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ARTICLE; CORONARY BLOOD VESSEL; DRUG COMBINATION; DRUG EFFECT; HUMAN; HYPERCHOLESTEROLEMIA; INTIMA; PATHOLOGY;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; CORONARY VESSELS; DRUG THERAPY, COMBINATION; HUMANS; HYPERCHOLESTEROLEMIA; SIMVASTATIN; TUNICA INTIMA;

EID: 51249083779     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.75.7.479     Document Type: Article

References (39)

1. Kastelein JJ. Akdim F, Stroes ES, et al; ENHANCE investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358:1431-1443.
2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-3421.
3. Grundy SM. Cleeman JI, Bairey Merz N. et al; for the Coordinating Committee of the National Cholesterol Education Program. Circulation 2004, 110:227-239.
4. Kastelein JJ. Sager PT, de Groot E. Veltri E. Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. Am Heart J 2005; 49:234-239.
5. Merck/Schering-Plough Pharmaceutical Press Release, January 14, 2008.
6. Berenson A. Study reveals doubt on drug for cholesterol. New York Times January 15, 2008.
7. Brown BG, Taylor AJ. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N Engl J Med 2008; 358:1504-1507.
8. Drazen JM, Jarcho JA, Morrissey S, Curfman GD. Cholesterol lowering and ezetimibe. N Engl J Med 2008; 358:1507-1508.
9. American College of Cardiology. ENHANCED analysis of ezetimibe. ACC News, April 2, 2008. www.acc.org/emails/myacc/ accnews%5Fapril%SF02%5F08.htm. Accessed 6/2/2008.
10. American College of Cardiology. ACC panel on Vytorin: Go back to statins. Scientific Session News 3/31/2008. http://www.acc08.acc.org/55N/ Documents/ACC%20Monday%20v2.pdf Accessed 6/2/2008.
11. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Endorsed by the National Heart Lung, and Blood Institute. J Am Coll Cardiol 2006; 47:2130-2139.
12. Pettypiece S, Cortez MF. Merck, Schering plunge as doctors discourage Vytorin. www.bloomberg.com/apps/ news?pid=20601103&refer=news&sid=aV_T9WirgAkl. Accessed 6/2/2008.
13. Barter PJ, Caulfield M, Eriksson M, et al; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357:2109-2122.
14. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280:605-613.
15. Rader DJ. Illuminating HDL - is it still 6 viable therapeutic target? N Engl J Med 2007; 357:2180-2183.
16. Davidson MH, Maki KC, Marx P, et al. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. Arch Intern Med 2000; 160:3315-3325.
17. Hodis HN, Mack WJ, Lobo RA, et al; Estrogen in the Prevention of Atherosclerosis Trial Research Group. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 135:939-953.
18. Turley SD. Cholesterol metabolism and therapeutic targets: rationale for targeting multiple metabolic pathways. Clin Cardiol 2004; 27(suppl 3):11116-11121.
19. Sehayek E, Hazen SL. Cholesterol absorption from the intestine is a major determinant of reverse cholesterol transport from peripheral tissue macrophages. Arterioscler Thromb Vasc Biol 2008; 27 [Epub ahead of print].
20. Davis HR Jr, Compton DS, Hoos L, Tetzloff G. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol 2001; 21:2032-2038.
21. Wong J, Quinn CPA, Gelissen IC, Jessup W, Brown AJ. The effect of statins on ABCA1 and ABCG1 expression in human macrophages is influenced by cellular cholesterol levels and extent of differentiation. Atherosclerosis 2008; 196:180-189.
22. Wang N, Tall AR. Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003; 23:1178-1184.
23. Bots ML. Carotid intima-media thickness as a surrogate marker for cardiovascular disease in intervention studies. Curr Med Res Opin 2006; 22:2181-2190.
24. Byington RP, Evans GW, Espeland, MA. et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1999; 1100:e14-e17.
25. Byington RP, Furberg CD, Crouse JR 3rd, Espeland MA. Bond MG. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 1995; 76:54C-59C.
26. Crouse JR 3rd, Rakhlen JS, Riley WA, et al; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 2007; 297:1344-1353.
27. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004, 110:3512-3517.
28. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357:577-581.
29. van Wissen S, Smilde TJ, Trip MD, Stalenhoef AFH, Kastellein JJP. Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. Am J Cardiol 2005; 95:264-266.
30. Meuwese MC, Franssen R, Stroes ES, Kastelein JJ. And then there were acyl coenzyme A:cholesterol acyl transferase inhibitors. Curr Opin Lipidol 2006; 17:426-430.
31. Kastelein JJ, van Leuven SI, Burgess L, et al; RADIANCE 1 Investigators. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356:1620-1630.
32. Nissen SE, Tuzcu EM, Brewer HB, et al; ACAT Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) investigators. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 2006; 354:1253-1263.
33. Davidson MH. Clinical significance of statin pleiotropic effects: hypotheses versus evidence. Circulation 2005; 111:2280-2281.
34. Nolting PR, de Groot E, Zwinderman AH, Buirma RJ, Trip MD, Kastelein JJ. Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia. Arch Intern Med 2003; 163:1837-1841.
35. Crouse JR 3rd, Grobbee DE, O'Leary DH, et al; Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin Study Group. Measuring effects on intima media thickness: an evaluation of rosuvastatin in subclinical atherosclerosis - the rationale and methodology of the METEOR study. Cardiovasc Drugs Ther 2004, 18:231-238.
36. Toth PP, Davidson MH. Cholesterol absorption blockade with ezetimibe. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5:455-462.
37. Nissen SE, Nicholls SJ, Sipahi I, et al; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295:1556-1565.
38. Kjekshus J, Apetrei E, Barrios V, et al; CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357:2248-2261.
39. Cannon CP, Braunwald E, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.